Ronald F. van Vollenhoven
Ronald F. van Vollenhoven
Ronald F. van Vollenhoven is Chair of the Department of Rheumatology and Clinical Immunology at the Amsterdam University Medical Centers (UMC) and Director of the Amsterdam Rheumatology and Immunology Center (ARC) in Amsterdam, the Netherlands. He received his MD and PhD degrees from the University of Leiden in the Netherlands. After graduating in 1984, he pursued immunology research at Cornell Medical College in New York (NY, USA), followed by a residency (specialty training) in internal medicine at the State University of New York at Stony Brook (NY) and a fellowship in rheumatology at Stanford University in Palo Alto (CA, USA). He then received an American Board of Internal Medicine certification in both internal medicine and rheumatology.
From 1993 to 1998, Prof. van Vollenhoven worked as Assistant Professor of Medicine in the Division of Immunology and Rheumatology at Stanford University and, from 1995, as Medical Services Chief and Fellowship Director. In 1998, Prof. van Vollenhoven moved to Stockholm, Sweden, where he worked as Senior Physician and Chief of the Clinical Trials Unit in the Department of Rheumatology at the Karolinska University Hospital and as Associate Professor of Rheumatology. In 2010, he was appointed as Professor and Chief of the Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID) at the Karolinska Institute. In January 2016, Prof. van Vollenhoven was appointed as Professor of Rheumatology at the University of Amsterdam and the VU University, and as Chair of Rheumatology at both the AMC and VUmc hospitals, all in Amsterdam, the Netherlands. In 2018, these faculties merged into the Department of Rheumatology and Clinical Immunology of the new Amsterdam UMC.
Prof. van Vollenhoven’s research interests focus around the development and systematic evaluation of biological and immunomodulatory treatments for rheumatic diseases. With his co-workers, he established the Stockholm registry for biological therapies (the STURE database), which supported research projects relating to clinical efficacy, pharmacology, outcomes, and pharmacoeconomics. He has been Principal Investigator in many clinical trials of novel therapies in rheumatic diseases and has contributed to several important investigator-initiated trials including the SWEFOT, ADMIRE, and DOSERA trials.
He has published over 300 original papers (H-index: 72), book chapters, and reviews, and is Associate Editor of Dubois’ lupus erythematosus (Elsevier, 2014), Editor of Clinical therapy research in the inflammatory diseases (World Scientific Press, 2015), Author of Biologics for the treatment of rheumatoid arthritis (Springer, 2015), and Co-Author, with Prof. Laurent Arnaud, of the Advanced handbook of systemic lupus erythematosus (Springer, 2017). In 2004, Prof. van Vollenhoven was awarded the Scandinavian Research Foundation Prize for excellence in clinical research in rheumatology; he is an honorary member of several rheumatological societies; and, in 2019, he received the highest award from the Dutch Rheumatological Society (NVR), the Jan van Breemen medal. He is the Editor-in-Chief of Lupus Science & Medicine, a member of the EULAR Executive, Past-Chair of the Swedish Rheumatology Society Professors’ Council, Co-Founder of the CERERRA registries collaboration and the NORD-STAR collaboration for Nordic trials in the rheumatic diseases, and Initiator of the Treat-to-Target-in-SLE and DORIS initiatives.
EM-31027 - Date of preparation: April 2020